Evidence map›Paper›PMID 41375013›Full record

ArticleCancers2025

Radiomic and Clinical-Pathological Factors Predictive of Postoperative Recurrence in Lung Neuroendocrine Tumors: A Pilot Study.

Piero Paravani, Michela Polici, Giulia Arrivi, Alessandra Siciliani, Massimiliano Mancini, Rossella Mazzilli, Virginia Zamponi, Maurizio Martiradonna, Federica Palmeri, Beatrice Trabalza Marinucci and 6 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Piero ParavaniEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, 00189 Rome, Italy.
Michela PoliciRadiology Unit, Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0001-7331-6901
Giulia ArriviOncology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant' Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0003-0541-415X
Alessandra SicilianiDivision of Thoracic Surgery, Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.
Massimiliano ManciniMorphologic and Molecular Pathology Unit, Sant'Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0001-7465-2229
Rossella MazzilliEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, 00189 Rome, Italy.
Virginia ZamponiEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, 00189 Rome, Italy.
Maurizio MartiradonnaEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, 00189 Rome, Italy.ORCID 0009-0000-9738-1070
Federica PalmeriRadiology Unit, Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.ORCID 0009-0004-8871-5947
Beatrice Trabalza MarinucciDivision of Thoracic Surgery, Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-3786-5716
Francesco PanzutoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, 00189 Rome, Italy.ORCID 0000-0003-2789-4289
Matteo TiracorrendoDivision of Thoracic Surgery, Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.
Antonio D'AndrilliDivision of Thoracic Surgery, Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.
Mohsen IbrahimDivision of Thoracic Surgery, Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.
Damiano CarusoRadiology Unit, Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0001-9285-4764
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, 00189 Rome, Italy.ORCID 0000-0002-9324-3946

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesNeuroendocrine tumors (NETs) of the lung account for about 30% of NETs. In localized and locally advanced forms, radical surgical resection is the standard of care. Although considered indolent tumors, they appear to be susceptible to post-surgical recurrence, with rates differing between typical and atypical carcinoid. Although still debated, several clinicopathologic factors are potentially associated with recurrence. The aim of this retrospective/prospective observational study is to evaluate the predictive role of clinicopathological factors and radiomics features in patients with NET of the lung.

methodsFrom January 2021 to April 2024, 45 consecutive patients who underwent radical (R0) surgery for lung NET at the ENETS Center of Excellence of the Sant'Andrea Hospital were enrolled, all with at least 12 months of postoperative follow-up and availability of preoperative unenhanced chest CT. Clinicopathologic and radiomic factors were considered (107 radiomic features). Of the individual characteristics, the impact on recurrence was assessed by univariate logistic regression.

resultsAmong the 45 patients included, 4 patients (8.9%) experienced disease recurrence. Among the clinicopathological features, major age at diagnosis (

conclusionsThis study has shown that radiomics can be a valuable tool in predicting recurrence. Currently, to our knowledge, no other studies on the possible application of radiomics as prognostic factors in patients with lung NET have been published. These encouraging findings warrant further investigations with larger, multicenter cohorts to validate these results and implement them by constructing a predictive model of recurrence.

Indexed as

carcinoidslung NETlung neuroendocrine tumorsNETprognostic factorsradiomics

Identifiers

PMID41375013
PMCPMC12691289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.